Kailera Moons 63% After Raising $625M With Zero Approved Drugs (Make It Make Sense)
“This MF’er don’t miss” - Big Pharma CEOs on Ron Renaud
Well friends, a company that was literally founded in 2024 with zero approved products just mooned 63% on its first day of trading. Kailera Therapeutics (perhaps you’ve heard?) raised $625 million in what became the biggest biotech IPO since 2021, popped to $26 from its $16 offering price, and is now casually worth $3.1 billion. (For selling exactly nothing at a pharmacy near you.)
The man steering this ship is The Exit Artist (read: Ron Renaud, Kailera's CEO), whose last three companies were all sold to Big Pharma for a combined $16 billion. Most recently he ran Cerevel Therapeutics until AbbVie swallowed it for $8.7 billion in 2024. Started Kailera approximately four seconds later. Translation: This man has one play and it works every friggin’ time. Note taken.
So what's the deal? Kailera is developing licensing four GLP-1 weight-loss drugs from Jiangsu Hengrui Pharmaceuticals, a Chinese biotech that did the actual science. Renaud says it himself: "It starts at Hengrui." The supply chain is built in the US, though. “Merica!.
The lead candidate, ribupatide, posted 23.6% body weight reduction in Phase 2 trials. That's competitive with Lilly's Zepbound, which just got its oral pill FDA-approved this month. Meanwhile, Novo Nordisk is bracing to take it even more on the chin for a 5-13% sales decline. “Wait, loss?”
Renaud's thesis is that pills don't cut it for severe obesity… patients with a BMI over 35 still need the needle. "We do not believe that injectables are things of the past," he said. And honestly, he's not wrong. When you're targeting the sickest patients, swallowing a pill ain't the answer.
But alas, keep in mind, Bain Capital pre-committed $225 million at the IPO price and will own roughly a third of the company post-offering. Qatar Investment Authority is also in. When your biggest backers are funding their own IPO at their own price, that's either supreme confidence or the most expensive self-high-five in biotech history. (Bold.) I respect it either way.
Moral of the story here? Ron Renaud licenses Chinese drugs, wraps them in a US-supply-chain bow, IPOs for half a billion, moons on day one, and eventually sells to Big Pharma for ten figures. Three companies. $16 billion in exits and now… #4 just entered the chat.Don’t hate the playa, hate the game, apparently. Until next time, friends...

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.